secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0001641172-25-017810
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity
----------------------------------------------------------------------------

- ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.
- Agent commission set at 3.0% of gross proceeds; sales at prevailing market prices on Nasdaq.
- Company has no obligation to sell any shares; agreement terminates upon full sale or earlier termination.
- Offering registered under existing S-3 shelf (File No. 333-279718); prospectus supplement filed July 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225017810/0001641172-25-017810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225017810/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer